TABLE 1.
Sociodemographic and clinical characteristics of immunocompromised children, classified as oncologic diagnosis, or immunosuppressive therapies/other immunocompromised status (n = 91)
| Demographics and clinical characteristics | Total (n = 91)N (%) | Oncology (n = 48)N (%) | Other immunosuppressive therapies/other immunocompromised status (n = 43)N (%) | p‐Value |
|---|---|---|---|---|
| Demographics | ||||
| Male | 58 (64) | 36 (75) | 22 (51) | .018 |
| Median age in years (IQR) | 15.5 (8.0–18.0) | 13.0 (5.0–17.0) | 17.0 (12.0–19.0) | .023 b |
| Race | ||||
| American Indian or Alaska Native | 3 (3) | 0 (0) | 3 (7) | .28 c |
| Asian | 1 (1) | 0 (0) | 1 (2) | |
| Black or African American | 4 (4) | 2 (4) | 2 (5) | |
| Race other | 25 (27) | 12 (25) | 13 (30) | |
| Race unknown | 5 (5) | 4 (8) | 1 (2) | |
| White | 53 (58) | 30 (63) | 23 (53) | |
| Ethnicity | ||||
| Ethnicity unknown | 3 (3) | 2 (4) | 1 (2) | .81 c |
| Hispanic or Latinx | 39 (43) | 19 (40) | 20 (47) | |
| Not Hispanic or Latinx | 49 (54) | 27 (56) | 22 (51) | |
| Asymptomatic during initial testing | 53 (58) | 31 (65) | 22 (51) | .20 |
| Initial testing done as outpatient | 61 (67) | 31 (65) | 30 (70) | .60 |
| Laboratory and microbiologic data | ||||
| At least one negative SARS‐CoV‐2 retest | 61 (67) | 42 (88) | 19 (44) | <.0001 |
| Median days to first negative test (IQR) | 31.0 (22.0–49.0) | 34.5 (23.0–50.0) | 28.0 (21.0–45.0) | .26 b |
| Two consecutive negative SARS‐CoV‐2 PCR tests | 54 (59) | 41 (85) | 13 (30) | <.0001 |
| Median days to first of two consecutive negative SARS‐CoV‐2 PCR tests | 35.0 (25.0–53.0) | 38.0 (25.0–55.0) | 30.0 (21.0–44.0) | .10 b |
| ANC within 72 hours of first positive SARS‐CoV‐2 PCR available | 64 (70) | 40 (83) | 24 (56) | .0041 |
| Median ANC within 72 hours of first positive SARS‐CoV‐2 PCR | 1686 (805.0–3160) | 1415 (630.0–2520) | 2710 (1310–3940) | .076 b |
| ALC within 72 hours of first positive SARS‐CoV‐2 PCR available | 62 (68) | 38 (79) | 24 (56) | .017 |
| Median ALC within 72 hours of first positive SARS‐CoV‐2 PCR | 920.0 (370.0–1370) | 550.0 (260.0–1370) | 1015 (885.0–1380) | .039 b |
| Clinical outcomes | ||||
| Initial hospitalization (related to COVID), n = 30 | 23 (77) | 13 (76) | 10 (77) | 1.000 c |
| ICU admission during first hospital stay, n = 30 | 3 (10) | 1 (6) | 2 (15) | .56 c |
Abbreviations: ALC, absolute lymphocyte count; ANC, absolute neutrophil count; COVID, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; PCR, polymerase chain reaction; SARS, severe acute respiratory syndrome.
a
Pearson's chi‐square test unless otherwise specified.
b
Wilcoxon rank‐sum test.
c
Fisher's exact test.